Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $131.97 USD
Change Today -1.16 / -0.87%
Volume 689.9K
VRTX On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VRTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/10/15 - $143.45
52 Week Low
09/29/15 - $97.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vertex pharmaceuticals inc (VRTX) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VRTX) Details

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, including lumacaftor in combination with ivacaftor, which has completed Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program. Further, it identifies and develops next-generation CFTR corrector compounds; and is involved in the research and early-stage development programs, including programs in the areas of oncology and neurology. Vertex Pharmaceuticals Incorporated sells its products principally to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. The company has collaboration agreements with Cystic Fibrosis Foundation Therapeutics Incorporated; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc, as well as a strategic research collaboration with CRISPR Therapeutics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,830 Employees
Last Reported Date: 02/13/15
Founded in 1989

vertex pharmaceuticals inc (VRTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $789.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $600.0K
Special Counsel to the Chief Executive Office...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2014.

vertex pharmaceuticals inc (VRTX) Key Developments

Vertex Pharmaceuticals Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer

Vertex Pharmaceuticals announced that it has appointed Michael J. Parini as its executive vice president and chief legal officer. Effective 4 January 2016, Parini will serve as a member of the company's executive committee, reporting directly to its chair, president and CEO, Jeffrey Leiden, MD, PhD. Parini most recently served as senior vice president and associate general counsel for the strategic management of Pfizer's global litigation activities, including civil, intellectual property, government and employment litigation, as well as worked as the chief counsel for multiple key business units within the company. Previously, Parini worked as a health care attorney at Akin, Gump, Strauss, Hauer & Feld LLP, where he provided legal counsel on federal and state regulatory and policy issues.

Vertex Pharmaceuticals Incorporated Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor)

Vertex Pharmaceuticals Incorporated announced that the European Commission has granted Marketing Authorization for ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation. In Europe, there are approximately 12,000 people with CF ages 12 and older who have two copies of this mutation. Vertex will now begin the country-by-country reimbursement approval process across the European Union (EU). The approval is based on previously announced data from two 24-week global Phase 3 studies, TRAFFIC and TRANSPORT, and additional interim 24-week data from the subsequent extension study, PROGRESS, in people ages 12 and older who have two copies of the F508del mutation and were already being treated with standard-of-care medicines. In the TRAFFIC and TRANSPORT studies, which enrolled more than 1,100 patients, those treated with the combination of lumacaftor and ivacaftor experienced significant improvements in lung function. Patients also experienced improvements in body mass index (BMI) and reductions in pulmonary exacerbations (acute lung infections) including those requiring hospitalizations and intravenous antibiotic use. Interim data from PROGRESS showed that these improvements were sustained through 48 total weeks of treatment (24 weeks in TRAFFIC/TRANSPORT + 24 weeks in PROGRESS). In addition, the pattern and magnitude of response observed after the initiation of combination treatment across all patients who received placebo in TRAFFIC and TRANSPORT and subsequently received a combination regimen in PROGRESS were similar to those seen among patients who received a combination regimen in TRAFFIC and TRANSPORT. The combination of lumacaftor and ivacaftor was generally well tolerated in all three studies. In TRAFFIC and TRANSPORT, the most common adverse events included shortness of breath and/or chest tightness, upper respiratory tract infection (common cold) and gastrointestinal symptoms (including nausea, diarrhea, or gas). In the extension study, the safety and tolerability results, including the type and frequency of adverse events and serious adverse events, were consistent with those observed in TRAFFIC and TRANSPORT, and no new safety concerns were identified. Over 48 weeks, the most common adverse events were infective pulmonary exacerbation, cough and increased sputum. The incidence of serious adverse events during PROGRESS was generally similar to TRAFFIC and TRANSPORT.

Vertex Pharmaceuticals Incorporated Receives Two European Commission Approvals for KALYDECO (ivacaftor) for People with Cystic Fibrosis

Vertex Pharmaceuticals Incorporated announced that the European Commission has approved expansion of the indication for KALYDECO (ivacaftor) to include children ages 2 to 5 with cystic fibrosis (CF) who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R) and to include people with CF ages 18 and older who have an R117H mutation. Ivacaftor was previously approved in the European Union (EU) for use in people with CF ages 6 and older who have one of nine gating mutations. In Europe, approximately 125 children with CF ages 2 to 5 have one of the nine gating mutations included in approval and approximately 350 adults with CF have an R117H mutation. Vertex will now begin the country-by-country reimbursement approval processes for each new indication. CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. In people with gating mutations, or an R117H mutation, the CFTR protein reaches the cell surface but does not work properly. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to help CFTR proteins at the cell surface open more often to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. Ivacaftor in Children Ages 2 to 5 with Gating Mutations: The European Commission’s Decision is based on previously announced results of a 24-week open-label Phase 3 study that was designed to evaluate the safety and pharmacokinetics of weight-based dosing of ivacaftor (50 mg or 75 mg twice daily) in children ages 2 to 5. A weight-based oral granule formulation of ivacaftor that is mixed in soft foods or liquids was created for these younger children and is available in two strengths, 50 mg and 75 mg. The approval also includes an extension of weight-based dosing of ivacaftor to children ages 6 to 11 who weigh less than 25 kg, using the new oral granule formulation. Ivacaftor in Adults with an R117H Mutation: The European Commission’s Decision is based on previously announced data from a Phase 3 study of ivacaftor that enrolled 69 people with CF who had an R117H mutation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $131.97 USD -1.16

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $74.06 USD -0.20
BioMarin Pharmaceutical Inc $96.06 USD -1.74
Incyte Corp $115.41 USD +3.69
Jazz Pharmaceuticals PLC $150.45 USD +3.43
United Therapeutics Corp $155.51 USD +1.28
View Industry Companies

Industry Analysis


Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.1x
Price/Book 35.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VERTEX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at